Ahn-Gook Pharmaceutical Co., Ltd. (001540.KQ) Stock

001540.KQ logo

Ahn-Gook Pharmaceutical Co., Ltd.

001540.KQSouth Korea
Healthcare

Company profile

Ahn-Gook Pharmaceutical reported revenue of 306.87 billion KRW for fiscal year 2025, up 13.2% from fiscal year 2024, and net income of 7.48 billion KRW. That is a net profit margin of 2.4% for fiscal year 2025. South Korea was its largest region in fiscal year 2024, with 98% of revenue. Our analysis of its filings shows revenue growing from 233.68 billion KRW in fiscal year 2023 to 306.87 billion KRW in fiscal year 2025, 14.6% a year on average.

What stands out

  • Net income fell 55.6% in fiscal year 2025, from 16.85 billion KRW in fiscal year 2024.
  • Revenue in fiscal year 2025 was the highest of the last 5 fiscal years.

Figures from company filings; latest fiscal year ended December 31, 2025.

About Ahn-Gook Pharmaceutical Co., Ltd.

Ahn-Gook Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products. The company's pharmaceutical products include Cinatura and Revo Tension. The company was founded in 1959 and is headquartered in Seoul, South Korea.

Largest shareholders

  • Jin Oh43.22 %43.22%
  • Ahn-Gook Pharmaceutical Co., Ltd.12.86%
  • Gwang Auh3.798 %3.80%
  • Myung-jin Oh0.4217 %0.42%
  • Ye-jin Oh0.4217 %0.42%

Share of the company, as of September 25, 2026

Leadership

  • June-Sun Auh — Chairman and Co-Chief Executive Officer, 88
  • Uh Jin — Co-Chief Executive Officer, President and Representative Director, 61
  • Chang-Gyun Han — Executive Officer and Director, 62

How much revenue does Ahn-Gook Pharmaceutical make?

Ahn-Gook Pharmaceutical reported 306.87 billion KRW in revenue for fiscal year 2025, up 13.2% from 271.12 billion KRW in fiscal year 2024.

Where does Ahn-Gook Pharmaceutical make most of its revenue?

South Korea: 98% of revenue by region in fiscal year 2024, followed by Overseas (2%).

What companies are similar to Ahn-Gook Pharmaceutical?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Jeil Pharmaceutical Co.,Ltd (271980.KS), Samsung Pharm. Co., Ltd. (001360.KS), Ilyang Pharmaceutical Co.,Ltd (007570.KS), Jeil Pharma Holdings Inc (002620.KS).

Has Ahn-Gook Pharmaceutical made a profit in recent years?

Net income by fiscal year: FY2021, 3.94 billion KRW; FY2022, 6.88 billion KRW; FY2023, 1.29 billion KRW; FY2024, 16.85 billion KRW; FY2025, 7.48 billion KRW. It was profitable in each of these years.

How has Ahn-Gook Pharmaceutical's revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2021, 163.53 billion KRW; FY2022, 205.39 billion KRW; FY2023, 233.68 billion KRW; FY2024, 271.12 billion KRW; FY2025, 306.87 billion KRW.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
HeadquartersSeoul, South Korea
ExchangeKOSDAQ
TimezoneAsia/Seoul (KST)

Contact & Links

Address
613 Siheung -daero, Seoul
Phone
82 2 3289 4226
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Ahn-Gook Pharmaceutical Co., Ltd. (001540.KQ)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/001540.KQ

LinkedInLinkedInXXYouTubeYouTube